


Exhibit 99.1

Alcon, Inc.

Slides used during the Alcon, Inc. AAO Presentation

November 7, 2008



**Alcon Investor
Meeting at AAO**

November 7, 2008

Alcon®

Safe Harbor Statement

This presentation, made on November 7, 2008, includes forward-looking statements based on current expectations and Alcon does not undertake the obligation to update the forward-looking information or statements. These expectations could differ materially from actual results and are subject to a number of uncertainties and risks as detailed in the company's form 20-F filed with the SEC on March 18, 2008.

In addition, this presentation may include several financial measures, to assist in better understanding our business, that are not prepared in accordance with generally accepted accounting principles (GAAP). These non-GAAP financial measures will be reconciled at the end of this presentation or in associated public information filed with the SEC.

Reports noted above are available on our website at www.alcon.com in the "Investors and Media" section. For further information contact the Alcon Investor Relations Department at (817) 551-8805.

The Alcon logo is located in the bottom right corner of the slide. It consists of the word "Alcon" in a bold, sans-serif font, with a registered trademark symbol (®) to its upper right. The background of the slide features a decorative pattern of small, overlapping circles in shades of blue and purple.

Agenda

Topic	Speaker
Opening Remarks	Cary Rayment
Product Growth Drivers	Kevin Buehler
Question & Answer Session	Cary Rayment Rick Croarkin Kevin Buehler Sabri Markabi, PhD

The Alcon logo is located in the bottom right corner of the slide. It features the word "Alcon" in a bold, black, sans-serif font, with a registered trademark symbol (®) to its upper right. The logo is positioned on a white rectangular background that contrasts with the dark blue patterned footer area.

Long Term Favorable Business Model


- Diversified business model with multiple sources for growth
 - Global reach and leadership unmatched
- Solid long term fundamentals underlie our markets and our business
- New products in pipeline at all stages of development
- Long history of solid execution and financial performance
- Long term business model of 8-10% organic sales growth and positive margin evolution remains intact



Alcon[®]

Alcon in the Current Market Environment

- **Clear appreciation for current economic environment and potential impact on markets and our business**
- **Expect to deliver lower end of long term organic growth range in 2009**
 - Economic Impacts and TobraDex®
- **Facing currency headwind of 5-6% in 2009 (at current rates)**
- **Commercial operations expansion largely complete for now**
 - Expect P&L leverage from investment in infrastructure
 - Making business decisions to deliver margin improvement
- **Reviewing investment portfolio**
- **Expanding investment in research and in-licensing**
 - Focusing on Glaucoma, Retina and Dry Eye

The Alcon logo is located in the bottom right corner of the slide. It consists of the word "Alcon" in a bold, black, sans-serif font, with a registered trademark symbol (®) to its upper right. The logo is positioned on a light gray background that is part of a decorative footer bar featuring a pattern of small, overlapping circles.

Research and Development Projects

Glaucoma

- **AZARGA®** a new glaucoma combination ex-US (Approval Pending)
- **Travatan® Z** clinical differentiation (Phase IV)
- **Anezortave Acetate** for Glaucoma studies and represents a shift in patient compliance (Phase II)

Retina

- **RTKi** compound for wet AMD (Phase II)
- **Tandisprone** for dry AMD (Phase I)

Cataract

- **ReSTOR® Aspheric +3.0 IOL** in U.S. (PMA filed in Q2 2008)
- **AcrySof® Toric** higher power lenses (Advanced development)
- **AcrySof® Phakic IOL** (CE Marked in EU, Advanced Development in U.S)
- **AcrySof® ReSTOR® Aspheric Toric IOL** (Early Development)

The Alcon logo is located in the bottom right corner of the slide. It features the word "Alcon" in a bold, black, sans-serif font, with a registered trademark symbol (®) to its upper right. The logo is positioned on a white rectangular background that contrasts with the dark blue patterned footer area.

Product Growth Drivers

Advanced Technology
IOLs

New Equipment
Platforms

New Glaucoma
Formulations

Alcon[®]

Product Growth Drivers

Advanced Technology
IOLs

New Equipment
Platforms


New Glaucoma
Formulations

Alcon[®]

Alcon Remains the #1 Choice in PC-IOLs


PC-IOL Usage Share as a % of Surgeons

4Q 2007



■ ReSTOR/ReSTOR Aspheric
■ ReZoom+
■ Crystallens+

3Q 2008



■ ReSTOR/ReSTOR Aspheric
■ ReZoom+
■ Crystallens+
■ Crystallens HD+

*Trademarks are property of their respective owners.

Source: Alcon Internal Data

Alcon

AcrySof® ReSTOR® +3.0 Key Benefits



AcrySof® ReSTOR® +3.0

- Received CE mark in Q3 2007
- Announced ex-U.S. launch at ESCRS in September
- Filed PMA with FDA in Q2 2008, expecting response by early 2009

- Aspheric acrylic design based on highly biocompatible AcrySof® Materials
- Maintains all visual performance benefits of +4.0 at near, intermediate and distance
- Extends reading distance by 7cm (2.8 in)
- Improves intermediate visual acuity by 1 – 1.5 line(s)
- Aspheric optic provides improved image quality
- Higher rate of patient satisfaction and spectacle independence

Alcon

Visual Acuity Comparison of the ReSTOR® Lenses

Improved Vision at All Distances

	ReSTOR® Aspheric +3.0	ReSTOR® Aspheric +4.0
20/20 or Better	31.2%	8.4%
20/25 or Better	81.8%	21.4%
20/32 or Better	86.2%	49.6%
20/40 or Better	94.9%	71.8%
Worse than 20/40	5.1%	28.2%

Note: Comparison of ACRYSOF® ReSTOR® Aspheric 3 months postoperatively after binocular implantation.

Data on file. Alcon, Inc.

Alcon®

Mean Visual Disturbances



*Trademarks are property of their respective owners.

Images provided by Jim Schwiegerling at the University of Arizona.

Alcon[®]

AcrySof® Toric Distinguishing Characteristics



AcrySof® Toric

**Precise astigmatic
correction**

**Unparalleled rotational
stability**

**Distance vision and
spectacle freedom**

**Calculator for precise
surgical planning**

**Member of the proven
AcrySof® platform**

**Diopter extensions are in
development**

Alcon®

Near Full Penetration of AcrySof® Toric

**Penetration Rate Among
Toric Implanting Surgeons**



Source: US 2008 Internal Alcon Data

**U.S. Unit Market Share for
Toric Lenses as of Q2 2008**



Source: Market Scope Q2 2008

Alcon®

AcrySof® Phakic Lens Attributes

**Unique design and
biocompatible material**

**Low haptic force and vault
dynamic response**

**Small incision delivery with
minimal endothelial cell loss**

**Effective visual correction
supported by clinical results**

**Refractive power range of
-6.0 to -16.5**

**Potential expansion to toric
and presbyopic correction**




AcrySof® Phakic
(Currently not available in the U.S.)

Alcon®

AcrySof® Phakic Lens Effects on Visual Acuity

Change in Best Spectacle Corrected Visual Acuity from Pre-Operation

Over 50% of patients achieved one line or more increase over pre-op at both 1 and 3 years



US Status: Investigational device limited by Federal Law to investigational use only.


Data on file. Alcon, Inc.

Alcon

AcrySof® Phakic: Effects on Endothelial Cells

Mean Chronic Loss in Central ECD

**Minimal effect on Chronic Endothelial Cell Density (ECD)
with year 1 and 2 show gains in ECD**



Data shown is mean change with upper 90% confidence interval.

US Status: Investigational device limited by Federal Law to investigational use only.

Data on File. Alcon, Inc.

Alcon

Alcon at the AAO: IOLs

- **SOE: Astigmatism Correction with Alcon Toric IOLs**
 - Sunday, 11/9, 2:00-3:30 p.m., Georgia World Congress Center, Level 1, Hall B-5
- **Common Pitfalls of Presbyopia-Correcting IOLs: How to Predict and Prevent Failure**
 - Sunday, 11/9, 3:15-5:30 p.m., Georgia World Congress Center, Room B406
- **Optical Performance of 3D- and 4D-Add Adapted Diffractive IOLs, Full-Aperture Diffractive IOLs and Zonal Refractive IOLs in a Model Eye**
 - Monday, 11/10, 12:30-2:00 p.m., Georgia World Congress Center, Level 1, Hall B-5
- **Evaluation of Postoperative Rotational Stability of the AcrySof® Toric IOL Using a New Software**
 - Monday, 11/10, 12:30-2:00 p.m., Georgia World Congress Center, Level 1, Hall B-5

The Alcon logo is displayed in a bold, black, sans-serif font. It is positioned on the right side of a horizontal bar that features a pattern of small, overlapping circles on the left and a solid dark blue background on the right.

Product Growth Drivers

Advanced Technology
IOLs

New Equipment
Platforms

New Glaucoma
Formulations

Alcon[®]

LAUREATE™ World Phaco System

LAUREATE™ Target Strategy

- Entry to mid-level phaco system
- Significant potential in emerging markets
- Enables an entry point to the Alcon portfolio of products for lower tier surgeons

LAUREATE™ Features

- Traditional ultrasound technology without QZil® torsional handpiece
- Innovative fluidic management
- Easy to use graphic user interface




Alcon

Vitreoretinal Equipment Share Development



U.S. ACCURUS[®]
Installed Base Share Growth



Historical estimation based on trends,
1997-2004

Source: Internal Alcon Surveys, 1999 - 2000

Alcon

CONSTELLATION® Improvements over ACCURUS®



Alcon®

ULTRAVIT® Vitrectomy Probe Features

■ High Speed Vitrectomy Probe

- 5000 CPM and variable duty cycle control (standard 2500 CPM)
- Allows for more physician control and enables work closer to the retina



Alcon®

Alcon at the AAO: Surgical Equipment

- **CONSTELLATION® Vision System Clinical Experiences Panel Discussion**
 - Sunday, 11/9, 9:45 a.m., Georgia World Congress Center, Alcon Booth #1300
- **CONSTELLATION® Vision System: Challenging Cases Panel Discussion**
 - Sunday, 11/9, 1:30 p.m., Georgia World Congress Center, Alcon Booth #1300
- **Architectural Design for CONSTELLATION® Vision System**
 - Monday, 11/10, 10:35 a.m., Georgia World Congress Center, Alcon Booth #1300

The Alcon logo is displayed in a bold, black, sans-serif font. It is positioned on the right side of a horizontal bar that features a pattern of small, overlapping circles on the left and a solid dark blue background on the right.

Product Growth Drivers

Advanced Technology
IOLs

New Equipment
Platforms

New Glaucoma
Formulations

Alcon[®]

Growing the TRAVATAN® Family

Alcon Global Prostaglandin Market Share

TRAVATAN® Family has gained 3.8 share points following DuoTrav™ and TRAVATAN Z® launches



U.S. Rx Share of TRAVATAN Z® as a Percentage of the Total TRAVATAN® Franchise


TRAVATAN® Franchise is up 6.3 share points since TRAVATAN Z® launch



Alcon

Continued Development of DuoTrav™

DuoTrav™ Market Share in EU, Australia and Canada




Source: IMS

Alcon

Azopt® Gaining Global Market Share

Global TCAI Market Share Development



* Trusopt is a registered trademark of Merck.

Source: IMS

Alcon®

Expanding Glaucoma Product Portfolio

AZARGA® Suspension

- Brinzolamide 1% / Timolol 0.5% fixed combination
- Powerful efficacy, superior comfort
- European marketing application filed in 4Q 2007
 - Positive opinion received



Alcon®

Favorable Patient Response

Ocular Comfort



Patient Preference



* COSOPT is a registered trademark of Merck.

Wong RK, Pavesi RM, Schwartz RH, et al. A side-by-side comparison of the ocular comfort of AZARGA and COSOPT. *Journal of Ocular Pharmacology and Therapeutics*. 2007;22(1):1-10. http://www.alcon.com/usa/azarga/clinical/clinical_trials/clinical_trials.asp

Mason TK, Pavesi RM, Williams RD, et al. A patient preference comparison of AZARGA and COSOPT. *Journal of Ocular Pharmacology and Therapeutics*. 2007;22(1):11-15. http://www.alcon.com/usa/azarga/clinical/clinical_trials/clinical_trials.asp

Alcon

Gaining Market Share in Pharmaceuticals

<u>RX Growth</u>	Global June YTD		US September YTD		US September 2008
	Brand	Market	Brand	Market	Market
TRAVATAN® Family	16.3%	8.3%	13.4%	-0.6%	4.4%
Azopt®	7.7%	6.1%	16.1%	4.4%	5.1%
Vigamox® ¹	20.6%	7.7%	-2.3%	-4.3%	-0.7%
TobraDex®	6.8%	7.4%	-7.9%	-4.1%	0.8%
NEVANAC®	62.2%	3.4%	21.5%	9.8%	11.5%
Patanol® + Pataday™	23.1%	2.3%	-2.7%	-8.3%	-3.1%
CIPRODEX® / Cipro HC	7.4%	0.3%	7.6%	0.3%	4.3%

¹ Moxifloxacin, the active ingredient in Vigamox®, is licensed to Alcon by Bayer HealthCare AG.
CIPRODEX® is a registered trademark of Bayer AG and licensed to Alcon by Bayer HealthCare AG.

Source: Global IMS US-WN Health


Alcon

Alcon at the AAO: Glaucoma

- **Optimizing Patient Care: Managing Glaucoma and Ocular Surface Disease: A Care-Based Interactive Discussion (an Ophthalmology Times Educational Symposium)**
 - Sunday, 11/9, Marriott Marquis
 - 6:00-6:30 a.m. Registration
 - 6:30-8:00 a.m. Symposium

- **A Study of Anecortave Acetate (7.5 and 15 mg) vs. Vehicle in Patients with Open-Angle Glaucoma**
 - Monday, 11/10, 8:30-8:38 a.m., Georgia World Congress Center, A411

Alcon



Alcon Investor Meeting at AAO

November 7, 2008

Alcon

AcrySof® Phakic Lens Attributes

**Unique design and
biocompatible material**

**Low haptic force and vault
dynamic response**

**Small incision delivery with
minimal endothelial cell loss**

**Effective visual correction
supported by clinical results**

**Refractive power range of
-6.0 to -16.5**

**Potential expansion to toric
and presbyopic correction**



AcrySof® Phakic

(Currently not available in the U.S.)

Alcon®